Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.54 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | WDR5 | P61964 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.54 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.54 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.54 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.54 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.54 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.54 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.54 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL14482079 | 1.00 | CYP2C9 (0.55) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL15266173 | 0.95 | CYP2C9 (0.55) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL15265927 | 0.95 | CYP2C9 (0.55) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL356522 | 0.95 | CYP2C9 (0.57) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL1457602 | 0.95 | CYP2C9 (0.57) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL14482156 | 0.94 | CYP2C9 (0.54) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL14483264 | 0.93 | CYP2C9 (0.54) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL14483267 | 0.93 | CYP2C9 (0.54) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1457172 | 0.93 | CYP2C9 (0.59) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL1457174 | 0.93 | CYP2C9 (0.59) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012714-A1 | NOVEL SOLVATE OF DEXLANSOPRAZOLE | CYP2D6, CYP2S1, CYP2F1 | ATP4A 1875/4885ATP4B 1464/4885CYP2C9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.